23 January 2020 - If approved by Health Canada, Perseris would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.

HLS Therapeutics announces that its new drug submission for Perseris, a novel long-acting injectable risperidone product for the treatment of schizophrenia was accepted for review by Health Canada on 23 January 2020. HLS is seeking approval for Perseris with an indication for the treatment of schizophrenia in adults.

HLS has in-licensed the exclusive rights to Perseris for the Canadian market from Indivior.

Read HLS Therapeutics press release